mRNA display is a powerful in vitro selection and directed evolution technique that enables the screening of trillions of peptide variants for desired functions in a single experiment. Compared to other display technologies, such as phage display, mRNA display offers distinct advantages, including ultra-high-diversity libraries, in vitro selection, and the ability to incorporate noncanonical amino acids. As a result, mRNA display has become the leading display technique for discovering novel (macrocyclic) peptide binders with antibody-like affinities and even potential oral bioavailability.
PeptiFinder Biotech is the pioneering CRO specializing in mRNA display technology, providing cutting-edge services to the pharmaceutical industry. PeptiFinder mRNA display platform offers various libraries (linear, monocyclic, and bicyclic peptides) with ultra-high-diversity (up to 10^15), which can be readily screened against almost any biological target of interest (6-8 weeks) with a remarkable success rate of over >95%. Furthermore, by incorporating unnatural amino acids into macrocyclic peptide libraries, PeptiFinder mRNA display platform can generate peptide hits with enhanced physiochemical properties and optimized pharmacokinetics, streamlining the process of optimizing lead compounds into clinical candidates and accelerating drug discovery timelines for clients. PeptiFinder also offers customer library service tailored to specific client needs.
